RYTHMODAN 100 MG — DIN 02224801
DISOPYRAMIDE : 100 MG · CHEPLAPHARM ARZNEIMITTEL GMBH · CAPSULE · wholesale supply in Canada
Health Canada status: DORMANT
What is RYTHMODAN?
RYTHMODAN 100 MG contains DISOPYRAMIDE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02224801, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as dormant, status dated 28-Jun-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
How much does Disopyramide cost around the world?
Disopyramide is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 2 | 6 | USD███.██ |
| Australia | ex-manufacturer | 3 | 3 | AUD███.██ |
| United Kingdom | hospital | 1 | 1 | GBP███.██ |
| Morocco | PPV (public price) | 1 | 1 | MAD███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
12 pack listings across 8 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Disopyramide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Disopyramide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Disopyramide, across 12 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HOECHST ROUSSEL CANADA INC. | 3 | 0 | RYTHMODAN CAPSULES 100MG, RYTHMODAN CAPSULES 150MG, RYTHMODAN-LA 250MG | No marketed DIN |
| ROUSSEL CANADA INC. | 3 | 0 | RYTHMODAN CAP 100MG, RYTHMODAN CAP 150MG, RYTHMODAN LA TAB 250MG | No marketed DIN |
| ROBERTS PHARMACEUTICAL CANADA INC. | 2 | 0 | NORPACE CAP 100MG, NORPACE CAP 150MG | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 2 | 0 | RYTHMODAN, RYTHMODAN-LA | No marketed DIN |
| CHEPLAPHARM ARZNEIMITTEL GMBH | 1 | 0 | RYTHMODAN | No marketed DIN |
| SHIRE BIOCHEM INC | 1 | 0 | NORPACE CR 150MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 100 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Disopyramide |
|---|---|
| ATC code | C01BA03 |
| AHFS class | 40:28.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02224801 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2224801 |
| Brand name | RYTHMODAN |
| Generic / active ingredient | DISOPYRAMIDE : 100 MG |
| Market authorization holder | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Health Canada schedule | Prescription |
| ATC code | C01BA03 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C01BA |
| Current status | DORMANT |
| Status date | 28-Jun-2026 |
| Original market date | 1997-08-20 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| NORPACE CAP 100MG | 100 MG | CAPSULE | ROBERTS PHARMACEUTICAL CANADA INC. | CANCELLED POST MARKET | 02030799 |
| NORPACE CAP 150MG | 150 MG | CAPSULE | ROBERTS PHARMACEUTICAL CANADA INC. | CANCELLED POST MARKET | 02030802 |
| NORPACE CR 150MG | 150 MG | TABLET (EXTENDED-RELEASE) | SHIRE BIOCHEM INC | CANCELLED POST MARKET | 02030810 |
| RYTHMODAN | 150 MG | CAPSULE | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02224828 |
| RYTHMODAN CAP 100MG | 100 MG | CAPSULE | ROUSSEL CANADA INC. | CANCELLED POST MARKET | 00382876 |
| RYTHMODAN CAP 150MG | 150 MG | CAPSULE | ROUSSEL CANADA INC. | CANCELLED POST MARKET | 00439363 |
| RYTHMODAN CAPSULES 100MG | 100 MG | CAPSULE | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | 01989553 |
| RYTHMODAN CAPSULES 150MG | 150 MG | CAPSULE | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | 01989561 |
| RYTHMODAN LA TAB 250MG | 250 MG | TABLET (EXTENDED-RELEASE) | ROUSSEL CANADA INC. | CANCELLED POST MARKET | 00619760 |
| RYTHMODAN-LA | 250 MG | TABLET (EXTENDED-RELEASE) | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02224836 |
2 · Same class — other molecules in ATC C01BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Procainamide | APO-PROCAINAMIDE CAP 250MG · APO-PROCAINAMIDE CAP 375MG · APO-PROCAINAMIDE CAP 500MG · PROCAINAMIDE HYDROCHLORIDE INJECTION USP · +9 more | 15 | 1 | Yes |
| Quinidine | APO QUINIDINE TAB 200MG · APO-QUIN-G TAB 325MG · BIQUIN DURULES 250 MG · CARDIOQUIN TABLETS · +11 more | 17 | 0 | Not in Canada |
| Disopyramide | NORPACE CAP 100MG · NORPACE CAP 150MG · NORPACE CR 150MG · RYTHMODAN · +7 more | 12 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C01BC | Flecainide · Propafenone | 35 | 16 |
| C01BD | Amiodarone · Bretylium Tosilate · Dronedarone · Ibutilide | 43 | 14 |
| C01BB | Lidocaine · Mexiletine · Tocainide | 22 | 8 |
| C01BG | Vernakalant | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is RYTHMODAN called?
The same molecule, Disopyramide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Rythmodan (Japan) | Latin | Australia |
| Rythmodan (UK) | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.